{
  "extraction_metadata": {
    "timestamp": "2025-10-01T13:40:05.489332",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 12,
    "total_picos": 11,
    "temperature": 0.2
  },
  "picos_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "AT",
      "PICOs": [
        {
          "Population": "patients with advanced NSCLC with a KRAS-G12C mutation that has progressed after at least one systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 7,
      "ContextTokens": 1555
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Patients with Stage IV NSCLC with a KRAS-G12C mutation should be treated according to Failure of at least one systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Sotorasib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 2,
      "ContextTokens": 346
    },
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sotorasib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 8,
      "ContextTokens": 1732
    },
    "EL": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EL",
      "PICOs": [
        {
          "Population": "pretreated patients with MCS carrying the KRAS p.G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 1,
      "ContextTokens": 331
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "PICOs": [],
      "Error": "Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4.1 in organization org-qjlBCLCPywLruyzWD3MengrF on tokens per min (TPM): Limit 30000, Used 23850, Requested 6154. Please try again in 8ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}",
      "ChunksUsed": 24,
      "ContextTokens": 4661
    },
    "ES": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "ES",
      "PICOs": [],
      "ChunksUsed": 1,
      "ContextTokens": 252
    },
    "EU": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EU",
      "PICOs": [],
      "ChunksUsed": 1,
      "ContextTokens": 159
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell adagrasib bronchial cancer (ASBC) with KRAS G12C mutation, whose disease has progressed after at least one prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 7,
      "ContextTokens": 1682
    },
    "IE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IE",
      "PICOs": [],
      "ChunksUsed": 1,
      "ContextTokens": 246
    },
    "IT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IT",
      "PICOs": [
        {
          "Population": "metastatic, p. G12C mutant KRAS NSCLL patients progressing following prior platinum-based chemotherapies",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "chemotherapy",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 5,
      "ContextTokens": 1048
    },
    "NL": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with non–small-cell lung cancer stage IIIB/IV and a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": ""
        },
        {
          "Population": "patients with non–small-cell lung cancer stage IIIB/IV and a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "chemotherapy",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 6,
      "ContextTokens": 1337
    },
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "patients with the KRAS G12C mutation are recommended treatment with sotorbasin following progression from prior systemic cytostatic and/or immune cell therapies",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sotorbasin",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 5,
      "ContextTokens": 1151
    }
  }
}